Literature DB >> 14607939

Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection.

Admar Verschoor1, Mark A Brockman, Mihaela Gadjeva, David M Knipe, Michael C Carroll.   

Abstract

The complement system, in addition to its role in innate immunity, is an important regulator of the B cell response. Complement exists predominantly in the circulation and although the primary source is hepatic, multiple additional cellular sources have been described that can contribute substantially to the complement pool. To date, however, complement produced by these secondary sources has been deemed redundant to that secreted by the liver. In contrast, using a bone marrow chimeric model, we observed that C3 synthesis by myeloid cells, a relatively minor source of complement, provided a critical function during the induction of humoral responses to peripheral HSV infection. Anti-viral Ab, as generated in an efficient humoral response, has been associated with protection from severe consequences of HSV dissemination. This report offers insight into the generation of the adaptive immune response in the periphery and describes a unique role for a nonhepatic complement source.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607939     DOI: 10.4049/jimmunol.171.10.5363

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 2.  The role of the complement system in innate immunity.

Authors:  Horea Rus; Cornelia Cudrici; Florin Niculescu
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection.

Authors:  Christopher B Brooke; Alexandra Schäfer; Glenn K Matsushima; Laura J White; Robert E Johnston
Journal:  J Gen Virol       Date:  2011-12-28       Impact factor: 3.891

4.  Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells.

Authors:  Mark A Brockman; Admar Verschoor; Jia Zhu; Michael C Carroll; David M Knipe
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Authors:  Natasha M Girgis; Brian C Dehaven; Yuhong Xiao; Edward Alexander; Kendra M Viner; Stuart N Isaacs
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

6.  Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis.

Authors:  Lin Zou; Yan Feng; Yan Li; Ming Zhang; Chan Chen; Jiayan Cai; Yu Gong; Larry Wang; Joshua M Thurman; Xiaobo Wu; John P Atkinson; Wei Chao
Journal:  J Immunol       Date:  2013-10-23       Impact factor: 5.422

Review 7.  B cell acquisition of antigen in vivo.

Authors:  Santiago F Gonzalez; Lisa A Pitcher; Thorsten Mempel; Franziska Schuerpf; Michael C Carroll
Journal:  Curr Opin Immunol       Date:  2009-06-08       Impact factor: 7.486

8.  Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin.

Authors:  Marvin Lin; Na Yin; Barbara Murphy; M Edward Medof; Stephan Segerer; Peter S Heeger; Bernd Schröppel
Journal:  Diabetes       Date:  2010-06-28       Impact factor: 9.461

9.  Caveolin-1 modifies the immunity to Pseudomonas aeruginosa.

Authors:  Mihaela Gadjeva; Catherine Paradis-Bleau; Gregory P Priebe; Raina Fichorova; Gerald B Pier
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 10.  Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.

Authors:  Mark A Brockman; David M Knipe
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.